text:
The Human Papillomavirus (HPV) is generally recognized to be the direct cause of cervical cancer. The development of effective anti-HPV vaccines, included in the portfolio of recommended vaccinations for any given community, led to the consolidation in many countries of immunization programs to prevent HPV-related cervical cancers. In recent years, increasing evidence in epidemiology and molecular biology have supported the oncogenic role of HPV in the development of other neoplasm including condylomas and penile, anal, vulvar, vaginal, and oro-pharyngeal cancers. Men play a key role in the paradigm of HPV infection: both as patients and as part of the mechanisms of transmission. Data show they are affected almost as often as women. Moreover, no screening procedures for HPV-related disease prevention are applied in men, who fail to undergo routine medical testing by any medical specialist at all. They also do not benefit from government prevention strategies.
A panel of experts convened to focus on scientific, medical, and economic studies, and on the achievements from health organizations' intervention programs on the matter. One of the goals was to discuss on the critical issues emerging from the ongoing global implementation of HPV vaccination. A second goal was to identify contributions which could overcome the barriers that impede or delay effective vaccination programs whose purpose is to eradicate the HPV infection both in women and men.
The reviewed studies on the natural history of HPV infection and related diseases in women and men, the increasing experience of HPV vaccination in women, the analysis of clinical effectiveness vs economic efficacy of HPV vaccination, are even more supportive of the economic sustainability of vaccination programs both in women and men. Those achievements address increasing and needed attention to the issue of social equity in healthcare for both genders.
Keywords:HPV infection; Condylomas; Cervical cancer; Genital cancer; Oro-pharyngeal cancer; Anti-HPV vaccines; Universal vaccination; Vaccination programs; Incremental cost-effectiveness ratio
Human Papillomavirus (HPV) infection is the most widely spread sexually transmitted infection in some areas of the world, with up to 70% of the population expected to become infected at some point of their lifetime [1,2]. The majority of these infections are subclinical, unrecognized, and benign [3,4]. Since HPV was discovered to be the direct cause of cervical cancer [5,6], scientific data paired to the development of effective anti-HPV vaccines, accepted by health organizations, and included in the portfolio of recommended vaccinations for the community, have led to the consolidation in many countries of immunization programs to prevent HPV-related cervical cancers. Knowledge and experience accrued thus far, support and better address prevention programs in utilizing HPV vaccination for the benefit of the community. HPV infection, earlier correlated only to cervical carcinoma, today is acknowledged to be primarily responsible for cancerous and precancerous lesions of the genital area in both males and females and, in a lower percentage but with a not indifferent burden, of head and neck cancers [7,8]. Although HPV infections are known to be mainly a sexually transmitted disease, recent studies in non-sexually abused children infected with HPV suggest different forms of transmission [9,10]. Reports on the non-sexual transmission of anogenital warts, e.g. by prenatal mode, show the importance of maternal gynecologic history [11], and can help to understand better suspected sexual abuse in children [12]. Hand-genital transmission in adults should also be considered as a non-sexual means of transmission of HPV [13,14] although it has yet to be confirmed [15].
Until today, HPV prevention strategies through vaccination have targeted women mainly against cervical cancer. HPV vaccination, as efficacious means to reduce the development of cervical cancer in women in primary intervention strategies, has already been shown to be highly effective in reducing HPV-related lesions, such as genital warts as well as CIN 2/3 [16,17]. The significant declines in the proportion of young women found to have genital warts and the absence of genital warts in vaccinated women in 2011 suggests that the human papillomavirus vaccine has a high efficacy outside of the trial setting. Vaccination is undoubtedly a primary prevention tool; furthermore the expected eradication of the most prevalent HPV types will decrease the need of intense screening (secondary prevention) and cervical excisions for high grade disease (tertiary prevention). Now increasing evidence demonstrates how important the burden of HPV-correlated diseases also is in men. Epidemiological data show that in Europe and the USA, the burden of HPV-related head and neck cancers is carried mainly by men (4 times more than women), which shows that males are more than mere vectors [18,19]. Between 2006 and 2007 many countries have implemented HPV vaccination programs only for girls around 12 years of age. In the beginning the two available and approved vaccines were intended to target females only. After the approval of the quadrivalent vaccine (HPV4) indications for men, the USA, Canada, and Australia now recommend routine vaccination for both men and women. Men however are not yet included in nationally funded routine HPV vaccination programs in Europe (except Austria) and in many other countries.
Data on disease burden, vaccine efficacy, vaccine safety, cost-effectiveness, and social and ethical factors need to be taken into consideration when authorities decide to add men to European HPV vaccination programs. This paper summarizes the topics debated by a panel of experts convened to focus on scientific, medical, and economic studies, and on achievements from health organizations' intervention programs on the matter. The goal is to better develop a knowledge platform to be used to further support and promote eradication of HPV infections in both women and men. The discussion was structured to identify contributions which could overcome common barriers that impede or delay effective vaccination programs whose purpose is to eradicate the HPV infection in both women and men.
Natural history of HPV infection in women and men
The increased understanding of the natural history of HPV infection recently supported one of the main breakthroughs of medical science. HPVs are double-stranded DNA viruses that replicate within stratified squamous epithelia that need micro-abrasions or areas of transitional epithelium, such as in the cervix, anus, and tonsils, to be able to infect epithelial cells [20]. After infection, the virus makes use of the cells' normal DNA replication machinery to produce further viral genetic fragments at the supra-basal layer of the epithelium [20,21]. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. While the majority of the known HPV infections cause no symptoms in most people and are usually spontaneously cleared by the host, some types can cause warts while others may lead – in a few cases – to cancers of the cervix, vulva, vagina, penis, anus, and oro-pharynx. More than 130 genotypes of HPV have been described; types are divided into high risk and low risk according to their ability to produce benign or malignant lesions over time. The main high risk HPV types, classified as carcinogenic to humans by the International Agency for Research and Cancer (IARC) since 1995 [22], are HPV types 16 and 18, which are responsible of about 70% [2,23] of cervical cancers worldwide and most HPV-related pre-cancerous lesions in other anatomical regions whether genital or not [24,25]. Among the low risk types, HPV types 6 and 11 account for approximately 90% of genital warts. Seventy percent of infections are usually cleared after one year and 90% in two years [20,26]. However, when the infection caused by high risk (HR) genotypes of HPV, persists – in 5% to 10% of infected women – there is a high probability of developing precancerous lesions of the cervix, which can progress to invasive cervical cancer. This process usually takes 10-15 years, providing many opportunities for prevention, detection, and treatment of the pre-cancerous lesion involved [21]. Several models show that what one may consider today as remission of infection might not be remission at all [20]. As already mentioned, increasing evidence in epidemiology and molecular biology have supported the oncogenic role of HPV in the development of other genital cancers including penile, anal, vulvar, and vaginal cancers [27,28] and some oro-pharyngeal cancers [8,29-31] that share mucosal junction similarities, such as the anal and cervical areas [32]. Several risk factors seem to affect HPV infection, from the number of sexual partners [33,34] and oral contraceptive use [35] to smoking and alcohol: the latter ones particularly related to head and neck cancers [36]. Other risk factors have been studied including condom use [37] and circumcision [38,39]. In women, evidence suggests two HPV incidence high peak points at < 25 and around 45 years of age [40]. On the other hand, in men, HPV prevalence and incidence seem to be constantly high at all ages [41,42]. The most common lesions in both sexes are anogenital warts (AGW), mainly attributable to HPV types 6 and 11 (> 90%). Of these cases, 20-50% involve co-infection with other high risk HPV types [27,43]. In fact, studies have demonstrated that both in females and males, AGW patients have a higher risk of developing HPV-related cancers [44]. These results seem to contradict statements from the American Centers for Disease Control (CDC) (2010) which indicate that AGW, except in very rare and unusual cases, will not turn in cancer. The types of HPV that cause AGW are different from the types that can cause anogenital cancer; however, subjects with low risk (LR) HPV types should be considered at higher risk of having cancer by HPV 16 in the future. Knowledge of natural history and epidemiology of HPV in men is constantly increasing although it still remains less extensive than in women. Cancers related to HPV diagnosed every year in males have been shown to be approximately half the number of HPV-related cancer cases in women. This proportion of 1:2 (not 1:100 or 1:1000) is significant, without taking into account other less severe HPV-related diseases that have a higher incidence and life-long-prevalence in men than in women. HPV-16 and -18 are found to account for 90% of all HPV-related cancers in men [45]. The most recent studies in Europe show that 17,403 cancer cases in men are expected to be HPV-related, 15,497 of which are attributable exclusively to HPV types 16 and 18 vs 32,562 which are expected to be related to these two types in women [19]. In addition it has also been estimated that there will be around 650,000 new cases each year of genital warts, more than 50% of which are expected in men. Similar data are confirmed by the most recent WHO (World Health Organization) statistical report on HPV in Europe [46]. A recent study conducted by Baio et al. [47] showed that the burden of HPV-related disease in Italy behaves similarly to that in Europe, with males playing an important role. The latest CDC data [18] on burden of disease in males display the same trend as Hartwig et al. [19] with almost half the number of cases of HPV-related cancer as women determined in Europe. Overall an average of 33,369 HPV-associated cancers (10,8 per 100.000 population), were diagnosed annually: 21,290 among women (13,2 per 100.000 population) and 12,080 among men (8,1 per 100.000 population). Cervical cancer was the most common, and oropharyngeal cancer ranked as the second most common. HPV-related head and neck cancer incidence in the USA is already higher in men, and should no action be taken, is expected to exceed that of cervical cancer by 2020 [18]. Anal cancer is a rare cancer; however, it has a very high incidence in men who have sex with men (MSM), where the incidence is estimated to be equivalent to that in women with cervical cancer, ranging from 32.8% to 93.5% [48-50], with an estimated risk of anal cancer 30 times [51,52] and genital warts around 10 times [53] higher than in heterosexual men. However not all cancers termed "HPV-associated" reflect actual infections and the numbers judged to be HPV-attributable are only estimates. The same MMWR editorial concludes: "Population-based screening for non-cervical HPV-associated cancers is not recommended" [18].
Critical issues in HPV vaccination
Immunogenicity, safety, and clinical significance represent the critical issues on which to base the prospective of the eradicating HPV-related diseases through a global implementation of multivalent HPV vaccination.
Two vaccines are currently available to prevent HPV infection. The bivalent vaccine (HPV2) targets HPV types 16 and 18 [54], while the quadrivalent vaccine (HPV4) targets HPV types 6, 11, 16, and 18 [55]. Both vaccines have demonstrated high efficacy in the prevention of cervical precancerous lesions, long-term immunogenicity and efficacy, and to be safe and well tolerated in females up to 25 years of age. HPV4 vaccine has also demonstrated, together with the protection against cervical cancer, high efficacy against genital warts from HPV types 6 and 11, against vaginal and vulvar precancerous lesions, re-infection, persistent infection, and anal precancerous lesions (AIN 1,2,3 studied in an MSM population) [56-58]. HPV4 vaccine is also indicated for the use in females up to 45 years of age and in males up to 26 years of age by the European Medicines Agency (EMA) in Europe. Both vaccines are currently employed in girls in many national vaccination campaigns and have proven to be safe, well tolerated, and highly efficacious in preventing persistent infections and cervical diseases associated with specific HPV types among females [59]. Studies about long-term duration of efficacy are still ongoing for both vaccines, and are around 9 years without breakthroughs. Time is needed to clarify the issues of long-term duration of efficacy and immunogenicity and whether a vaccine boost will be required or not [60-62]. Through mathematical modeling Fraser et al. evaluated the long-term anti-HPV-16 responses following administration of a three-dose regimen of HPV-16 vaccine in women aged 16-23 years. Using a conventional power law model a median duration of detectable antibody (> 5.9 mMU/mL) of 32 years has been estimated; whereas the modified power law model predicted a long-term plateau of antibody duration with a nearly life-long persistence above the level of detection (> 5.9 mMU/mL) [63].
As mentioned before, the HPV burden of disease has been demonstrated to be quite high in men as well. Recent randomized studies have been conducted in order to assess efficacy, immunogenicity, and safety of the quadrivalent vaccine in men and included 4,065 young male subjects aged between 16 and 26 years of age, 602 of which self-declared to have sex with other men. Vaccine efficacy against external genital lesions (EGL) was found to be 90.4% and 89.4% against genital warts [56] (Table 1). The study by Giuliano and colleagues showed efficacy of 92.4% against genital warts in the heterosexual male population and 79% in the MSM population; for persistent infection the vaccine proved to have an efficacy of 50.4% for heterosexual males and 43.6% for MSM [56]. The same trial conducted to evaluate any grade of anal intraepithelial neoplasia (AIN) in MSM showed an overall efficacy on the per protocol population of 77.5% [57]. An exclusively post-hoc efficacy analysis for vaccine types of 92% was reported [58]. The studies [56-58] on male vaccine efficacy are summarized in Table 2. Efficacy of vaccine was bridged to males 10-15 years old with an immune-bridging study that demonstrated non-inferiority immune response compared to females aged 16 to 23 [64]. These studies are the basis for vaccine approval for males and male vaccination recommendations by EMA and FDA (Food and Drug Administration).
Table 1. HPV4 vaccine efficacy study against external genital lesions and persistent HPV infection in men 16-26 years of age (n = 4065) [56]
HPV vaccines have been demonstrated to be safe over the last 10 years. Most available data is on women, as they were the primary target of vaccination. Data on immunogenicity and safety are available however also for men and demonstrated that both HPV2 and HPV4 have immunogenicity and favorable safety profile similar to the studies conducted in women [65]. Both HPV vaccines are closely monitored worldwide and post-licensure studies have shown good safety profiles [66,67].
The clinical significance of HPV vaccination has been extensively studied in specific communities.
In the province of Victoria (Australia) an ecological study compared the incidence of high-grade pre-neoplastic and cancers (CIN 2+) lesions detected in women < 18 years of age examined before and after the start of an HPV4 vaccination program in young girls aged 12-to-13 years old [16]. A progressive decrease in the incidence of high-grade lesions by 0.38% has been observed in the girls younger than 18 years in a region where the vaccination coverage was between 71% and 79%. Another Australian ecological follow-up study [17] showed that after 5 years from the beginning of the vaccination program, genital incidence of new cases of genital wart dropped by 93%. Some herd immunity was also observed in males of the same age group, although incidence remained high in the MSM population [17]. Two other studies conducted in New Zealand [68] and California (USA) [69] – where the coverage of vaccination programs of the target population was rarely over 50% – showed around 60% and 30% reduction of genital warts, respectively. Evidence seems to support vaccine efficacy and reduction of disease with some herd immunity effect in heterosexual males but not in MSM. A rapid and marked reduction in the incidence of genital warts occurred among vaccinated women, and this reduction could mean some benefit being conferred to heterosexual men [70], but not to MSM. A rapid decline in presentation of genital warts was observed after implementation of a national program with HPV4 vaccine [70]. Given the success of Australia's catch-up program, it will not be long before we know if the basic reproductive number for genital warts holds the prospect of elimination. However, if genital warts stabilize at a lower, but not very low, rate we will know that elimination will not be possible without vaccination of males [71].
International policies and recommendations
Vaccination and vaccines are undoubtedly one of the most innovative procedures with the greatest impact on population health protection. Well-implemented vaccine policies achieve almost complete eradication of diseases once thought to be lethal.
In Europe, recommendations for HPV vaccination in females have been introduced in nearly all Western European countries with some of them also offering national or regional funding programs. It was first introduced in 2007 in Belgium, France, Germany, and Italy. In 2008 other countries also recommended vaccination, such as Greece, Luxembourg, the Netherlands, Romania, Spain, Switzerland, and the UK. Other European countries followed (Denmark, Norway, Portugal, San Marino, and Macedonia). The latest to start were Sweden and Ireland in 2010. As of today the vaccination advisory boards in 21 of the 29 countries of the EU have recommended and have in place active HPV vaccination programs [72]. In other countries (Czech Republic, Slovenia, Latvia, and Iceland), HPV vaccination has been recommended but has not been actually integrated in the national immunization programs. Some countries not only initiated their programs with the primary cohort of females but also have implemented different vaccination cohorts or catch-up programs. In Italy, the Basilicata region started in 2007/08 with a 4-cohort strategy covering females up to 25 years of age and assuring coverage of all females up to 21 years of age in 2012. This has resulted in average coverage rates in the primary cohort of around 80% and represents an excellent paradigm. Data collected by the VENICE2 Group in 2010 [72] registered a high heterogeneity in the strategies for implementation of the HPV vaccination in European countries. Recommendations for the vaccination starting age range from 10 to 18 and the catch-up rounds from age 12 to 24. So far the targets are girls/women in all European countries except Austria, which already targets but does not fund vaccination in males as well as females.
Today, in fact, the HPV4 vaccine is also indicated by the main health organizations (e.g. FDA, EMA) for males up to 26 years of age.
The US initially recommended routine vaccination of females between 11 and 12 years of age, with catch-up programs up to 26 years of age. Although the private American health system is not comparable to most public European health systems, the vaccine was offered for free both to the health-insured population and to the uninsured through Medicaid and the Vaccine for Children (VFC) program that offered the vaccine for free to girls up to 18 years of age. Even so, the US found several obstacles to reach high rates of vaccine coverage effectively in all regions, with an average coverage of only around 20% [73]. In 2011, the CDC Advisory Committee on Immunization Practices (ACIP) took into account new efficacy data on the vaccines, the low coverage rates, and the updated burden of disease knowledge and decided to recommend routine vaccination for both men and women, a gender-neutral vaccination offered free of charge, both to insured and uninsured people up to their 18th birthday [74]. To support this decision, the American Academy of Pediatrics [75] recommended the vaccination of males as well as females. This new strategy is expected to further reduce the burden of the disease. In 2007 Canada and Australia which have national health systems decided to vaccinate women at the start of the program through school-based programs. Doing so, vaccine coverage reached higher coverage rates, ranging from 63.7% to 79.6% in Australia and from 50% to 85% in Canada [76-78]. The latest epidemiological studies in Australia show an almost complete disappearance of genital warts diagnosis: with a coverage of 83% of women < 21 years who received the first dose of the vaccine, the diagnosis of genital warts declined by 93% by the fifth year of the national quadrivalent HPV vaccination program [17]. In late 2011 and early 2012, both PBAC (Pharmaceutical Benefits Advisory Committee) and the NACI (National Advisory Committee on Immunization) [78] vaccine bodies in Australia and Canada have decided to recommend routine HPV vaccinations for males and females; the program started in Australia in January 2013.
Since the EMA approval in 2011 of male vaccination with the HPV4 vaccine, no European country (except Austria) has developed and implemented a program for routine vaccination in boys.
Clinical effectiveness vs economic effectiveness
An overview of the results of many economic studies shows that vaccination against HPV produces immediate benefits from epidemiological points of view and in terms of avoided costs for country-specific National Health Systems (NHSs) [79-82]. Although estimates vary depending on the assumptions made, the cost-effectiveness of vaccination against HPV has been confirmed by a large body of modeling studies, which have been designed to evaluate different vaccination strategies [83,84]. In general, these studies compared a single cohort of women who underwent vaccination, plus optional catch-up cohorts, with women who underwent screening alone; the cohorts varied in age of immunization among studies. Studies evaluated the cost-effectiveness of vaccinating women of a particular age (e.g. 35 years) who had been participating in a specific screening strategy (e.g. biennial cytology) [85]. Two studies evaluated the implementation and economic consequences of a multi-cohort vaccination strategy [86,87]. At present, to be considered efficient from an economic point of view, health intervention should have an ICER (Incremental Cost Effectiveness Ratio) per QALY (Quality Adjusted Life Year) gained of less than £ 20,000 to £ 30,000 [88,89] (approximately € 30,000 to € 45,000). It should be noted that the threshold of £ 30.000 as defined by the National Institute for Health and Clinical Excellence (NICE) is not transferable to the specific policies on vaccines. The Canadian Agency for Drugs and Technologies in Health evaluated the cost-effectiveness of HPV vaccination in women and calculated a cost per QALY gained amounting to € 14,224 for the HPV4 vaccine and € 21,540 for the HPV2 vaccine [89]. Another study calculated QALY gained for HPV4 vaccines in Italy of € 9,569 [84]. In a recent study [87], results from a multi-cohort (12, 15, 16, and 25 years old) vaccination strategy of women confirmed the cost-effectiveness of HPV vaccination.
Several economic evaluations have assessed various HPV vaccine scenarios for men and women, on a cost-effectiveness basis in terms of QALY gained [79-81]. Even so, most cost-effectiveness studies of male vaccination tend to be centered on exclusively reducing cervical cancer in women and lack further important economic considerations – only lately have some studies started to take into account other vaccine benefits.
The published mathematical models using both men and women are based on assumptions that are not fully evidence-based. There are few studies that include males and those that are available also do not include all HPV-related diseases in both sexes and the coverage and compliance rates. Increasing coverage rates in females is a real challenge in most countries and is unlikely to be realized, unless a considerable budget effort is made by health authorities (public health campaigns, etc). The CDC recommendation (in November 2011) that young boys, as well as girls, should get immunized against HPV was based on the statement that male inclusion is cost-effective when coverage rates in females are low, such as is the case in the United States. In Australia, where the HPV vaccine coverage in female is high (> 80%), the decision to include routine vaccination of boys 12/13 years of age (recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) [90]) was supported by showing that male inclusion could be cost-effective in Australia [91]. Following the Australian example, in January 2012 the National Advisory Committee on Immunization (NACI) in Canada recommended extension of the HPV4 vaccine to males between 9 and 36 years of age and routine vaccination of 12-year-old boys [78]. When more non-cervical diseases are included, cost per QALY gained decreased significantly. Moreover, not incorporating the reduction of number of non-cervical cancer cases in both sexes leads to a substantial underestimation of the cost per QALY gained of extending the vaccination to males. Elbasha et al. [92] presented all epidemiological outcomes and the number of cases avoided by vaccinating males in addition to females. The most oncogenic HPV type causing the greatest burden may be the most difficult to eliminate through vaccination of girls only; more substantial incremental benefits are expected by adding boys to vaccination programs when the HPV vaccine coverage is < 50% among young girls [93]. The cost/effectiveness of the impact on the overall population of including routine vaccine to MSM is still to be better defined. Boys and girls will mostly benefit from HPV vaccination if vaccinated routinely before becoming sexually active. In addition to protecting heterosexual males and their female partners, routine vaccination of boys at a young age is also the best way to reach MSM at an age when they could most benefit [74]. Furthermore, in the early stages of sexual life for a significant number of MSM, heterosexual activity is not uncommon thus contributing to the transmission of the virus [94]. Burden of disease in men seems to be quite significant, because genital warts alone have an important economic and psychological burden. Models taking into consideration several factors such as other HPV-related diseases seem to prove that male vaccination is expected to be cost effective.
Introduction to male vaccination
One of the main goals of vaccination programs is to stop the transmission of an infective agent. In the case of HPV a single gender vaccination will not achieve such a goal. Moreover, why should vaccination programs target only one single disease such as cervical cancer, when vaccine benefits have also been proven to be high against other HPV-related diseases? Vaccinating boys is expected to facilitate the eradication of the cervical cancer, reduce the transmission of the virus, increase herd immunity, and contribute to the prevention of HPV-associated diseases in both genders. In fact more incremental benefits are expected by adding the boys in the vaccine program [93].
Neither the EMA nor the European Centre for Disease Prevention and Control (ECDC) guidelines [95] formally recommend vaccinating programs in boys or men. Among the scientific endorsements of an inclusion of males into vaccination programs for females, two different multidisciplinary panels of experts were convened between 2010 and 2012 in Italy. The Italian Society of Andrology, the Italian Society of Urologists, and the Italian Society of Andrology and Sexual Medicine created a panel of experts which developed a consensus statement arguing that the vaccine should be offered to males [96]. The second panel developed a commitment platform among scientists that is the basis of this paper. Italy is now also offering the vaccine on demand to males with a strategy of co-payment although informational and promotional campaigns have not been finalized yet.
Men play a key role in the paradigm of HPV infection: both as patients and as part of the mechanisms of transmission. As mentioned before, data show men are affected almost as frequently as women. Moreover no screening procedures for HPV prevention are currently ongoing in men, who do not receive routine medical testing by any medical specialist; in general the attitude in men towards prevention is low. They also do not benefit from government prevention strategies. It is well known that flat penile lesions play an important role in the transmission of high risk HPVs. In women the anal mucosa is a reservoir of HPV, which can be a source of re-infection for the cervix [97]. However, as observed in the mentioned study, there was not a significant association between the anal sex practice and the prevalence of anal cytological abnormalities. Including men in HPV vaccination programs increases its ranking on the list of urgent decisions to be taken by policy makers [98-101]. Information on HPV-related diseases is low or lacking in men; however, from studies focused on the acceptance by parents of vaccination of boys, it appears they would be willing to vaccinate their male children [102-104] and inclusion of men in the vaccine program will also increase coverage in women [105-107]. Discussion regarding the introduction of male vaccination is ongoing. Several key points could help in the extension of HPV vaccination programs to men such as: female-only vaccination will not protect all men; HPV-related head and neck cancer burden is carried mainly by men; it is the fastest way to achieve female protection by means of herd-immunity; vaccinating males is a more gender-equitable public health policy; men seem to accept vaccination as do parents of boys; vaccine seems to elicit the same if not a higher degree of immunogenicity in boys than in girls; genital warts and HPV-related cancers in men represent costly and emotionally burdensome and preventable conditions; lessons from the past with other vaccines show that single-gender-based vaccination policies are less effective.
"…there is a good chance of drastically reducing cervical cancer by vaccination…. HPV-16 and -18 could probably be eliminated if we have a global program. You could theoretically achieve this by vaccinating only girls, but you would need very high coverage. I'm a strong advocate for vaccinating boys as well: we'll reach the goal much faster by vaccinating both sexes. The disadvantage is that the cost is very high…"[108].
The HPV4 vaccine has proved to be effective and safe in men, but whether this is enough to recommend inclusion of males in NHS prevention strategies is still being debated. Several factors such as vaccine efficacy, herd immunity, vaccine coverage rates in females, burden of disease in men, and cost-benefit ratios need to be further evaluated when including men into the formula.
Achievements, pending questions, next steps
Vaccines are among the few medical interventions capable of achieving almost complete eradication of a disease. Today's available epidemiological data show that HPV do not affect men and women differently and that men carry a considerable burden of the disease, enough to justify being included in national recommendations for immunization programs against HPV-associated lesions. Both the EMA and the FDA have approved HPV4 vaccine indication in males 9-26 years of age. Some national public health authority boards, such as in the USA, Canada, and Australia, already recommend men being included in their anti-HPV national routine immunization programs. So far, except for Austria, it is not yet recommended in Europe.
Taking advantage of the increasing opportunity to reduce HPV infection and transmission among sex partners, and of the increasing evidence on the effectiveness/efficacy of the HPV vaccines in preventing the development of HPV-related diseases, will decrease the burden of disease and increase the quality of life in the communities.
Including boys in vaccination programs can produce more incremental benefits globally to the currently unsolved and severe problem of HPV infection [93,109].
Those achievements pose questions for decision-makers as to their duty to overcome any barrier that impedes the achievement of health protection for both women and men against HPV infection. The issue of social equity in healthcare for both men and women is also one that must be addressed.
Future evaluation by the decision-makers in various countries of the results obtained by the next generation of intervention programs will focus on the critical issues that still exist: a) previous experience in gender-restricted vaccination programmes has demonstrated a substantially lower effectiveness than universal vaccination;b) limiting vaccination to women might increase the psychological burden on women by confirming a perceived inequality of the sexes; c) even if all women were immunized, the HPV chain of transmission would still be maintained through MSM; d) the cost-effectiveness of including boys in HPV vaccination programs should be re-assessed in view of the increased reduction, due to universal vaccination, of the economic burden of HPV related diseases in men and women [110].
Therefore steps must be taken by recommendation bodies and stakeholders to achieve the expected results of universal vaccination - the eradication of HPV infection. The goal to eradicate sexually transmitted carcinogenic viruses can be accomplished jointly by women and men within a few decades [111].
ACIP: Advisory committee on immunization practices; AGW: Ano genital warts; AIN: Anal intraepithelial neoplasia; CDC: Centers for disease control and prevention; CIN: Cervical intraepithelial neoplasia; ECDC: European centre for disease prevention and control; EGL: External genital lesions; EMA: European medicines agency; FDA: Food and drug administration; HPV: Human papilloma virus; HPV2: HPV bivalent vaccine; HPV4: HPV quadrivalent vaccine; IARC: International agency for research and cancer; MSM: Men who have sex with men; NACI: National advisory committee on immunization; NHSs: National health systems; PBAC: Pharmaceutical benefits advisory committee; QALY: Quality adjusted life year; VENICE: Vaccine european new integrated collaboration effort; VFC: Vaccine for children; WHO: World health organization.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
The manuscript is a result of numerous discussions among the authors during three Workshops organized and moderated by the Fondazione Giovanni Lorenzini Medical Science Foundation (Milan, Italy and Houston, TX, USA). All authors have participated in writing the manuscript. All the authors have read and approved the final manuscript.
The manuscript is a result of the activity of a panel of experts convened by the Fondazione Giovanni Lorenzini Medical Science Foundation (Milan, Italy and Houston, TX, USA).
Baseman JG, Koutsky LA: The epidemiology of human papilloma virus infections.
J Clin Virol 2005, 32(Suppl 1):S16-S24. PubMed Abstract | Publisher Full Text
Kahn JA, Burk RD: Papillomavirus vaccines in perspective.
Lancet 2007, 369:2135-2137. PubMed Abstract | Publisher Full Text
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.
J Infect Dis 2010, 202(12):1789-1799. PubMed Abstract | Publisher Full Text
Syrjanen KJ: Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
Scand J Infect Dis Suppl 2009, 108:2-32. PubMed Abstract
Zur Hausen H, de Villiers EM, Gissmann L: Papillomavirus infections and human genital cancer.
Gynecol Oncol 1981, 12:S124-S128. PubMed Abstract | Publisher Full Text
Zur Hausen H: The search for infectious causes of human cancers where and why.
Virology 2009, 392(1):1-10. PubMed Abstract | Publisher Full Text
Tota J, Chevarie-Davis M, Richardson LA, Devries M, Franco EL: Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies.
Prev Med 2011, 53:S12-S21. PubMed Abstract | Publisher Full Text
Genden EM, Sambur IM, de Almeida JR, Posner M, Rinaldo A, Rodrigo JP, Strojan P, Takes RP, Ferlito A: Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know.
Eur Arch Otorhinolaryngol 2013, 270(2):405-416. PubMed Abstract | Publisher Full Text
LaCour DE, Trimble C: Human papillomavirus in infants: transmission, prevalence, and persistence.
J Pediatr Adolesc Gynecol 2012, 25:93-97. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Unger ER, Fajman NN, Maloney EM, Onyekwuluje J, Swan DC, Howard L, Beck-Sague CM, Sawyer MK, Girardet RG, Sautter RL, Hammerschlag MR, Black CM: Anogenital human papillomavirus in sexually abused and non abused children: a multicenter study.
Pediatrics 2011, 128(3):e658-e665. PubMed Abstract | Publisher Full Text
Jones V, Smith SJ, Omar HA: Nonsexual transmission of anogenital warts in children: a retrospective analysis.
ScientificWorldJournal 2007, 7:1896-1899. PubMed Abstract | Publisher Full Text
Honor G: Ano-genital in children: sexual abuse or not?
J Pediatr Health Care 2004, 18(4):165-170. PubMed Abstract | Publisher Full Text
Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM: Hand-genital transmission of genital warts? An analysis of prevalence data.
Epidemiol Infect 1995, 115:169-176. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Sonnex C, Strauss S, Gray JJ: Detection of human papillomavirus DNA on the fingers of patients with genital warts.
Sex Transm Inf 1999, 75:317-319. Publisher Full Text
Rachel L, Winer RL, Hughes JP, Feng Q, Fu Xi L, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA: Detection of genital HPV types in fingertip samples from newly sexually active female university students.
Cancer Epidemiol Biomarkers Prev 2010, 19(7):1682-1685. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.
Lancet 2011, 377:2085-2092. PubMed Abstract | Publisher Full Text
Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, Fairley CK, Guy RJ: Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.
BMJ 2013, 346:f2032.
Published 19 April 2013PubMed Abstract | Publisher Full Text
Morbidity and Mortality Weekly Reports
MMWR 2012, 61(No.15):258-261.
http://www.cdc.gov/mmwr/pdf/wk/mm6115.pdf webcitePubMed Abstract | Publisher Full Text
Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsaguè X: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review.
BMC Cancer 2012, 12:30. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text
Gravitt PE: The known unknowns of HPV natural history.
J Clin Invest 2011, 121(12):4593-4599. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Frazer IH: Prevention of cervical cancer through papillomavirus vaccination.
Nature Rev Immunol 2004, 4:46-55. Publisher Full Text
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer.
Lancet 2007, 370(9590):890-907. PubMed Abstract | Publisher Full Text
Frazer IH: Measuring serum antibody to human papillomavirus following infection or vaccination.
Gynecol Oncol 2010, 118(Issue 1, Supplement 1):S8-S11. PubMed Abstract | Publisher Full Text
Franco E, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE: Epidemiology and natural history of human papillomavirus infection in women from a high-risk area of cervical cancer.
Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.
Lancet 2001, 357(9271):1831-1836. PubMed Abstract | Publisher Full Text
Goldstein MA, Goodman A, del Carmen MG, Wilbur DC: Case records of the Massachusetts General Hospital. Case 10-2009. A 23-year-old woman with an abnormal Papanicolaou smear.
NEJM 2009, 360(13):1337-1344. PubMed Abstract | Publisher Full Text
Giuliano AR, Tortelero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX: Epidemiology of human papilloma virus infection in men, cancers other than cervical and benign conditions.
Vaccine 2008, 26(Suppl 10):K17-K28. PubMed Abstract | Publisher Full Text
Monk BJ, Tewari KS: The spectrum and clinical sequelae of human papillomavirus infection.
Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi SS, Vigili MG, Venuti A: Molecular analyses and prognostic relevance of HPV in head and neck tumours.
Oncol Rep 2007, 17:931-939. PubMed Abstract | Publisher Full Text
Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister H, Fuchs PG: Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas.
Cancer 2001, 92:2875-2884. PubMed Abstract | Publisher Full Text
De Stefani A, Boffano P, Averono G, Ramella A, Pia F, Bongioannini G: Prevalence and characteristics of HPV infection in oropharyngeal cancer.
J Craniofac Surg 2013, 24(1):e40-e43. PubMed Abstract | Publisher Full Text
Herfs M, Hubert P, Moutschen M, Delvenne P: Mucosal junctions: open doors for HPV and HIV infections?
Trends Microbiol 2011, 19:114-120. PubMed Abstract | Publisher Full Text
Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, Papenfuss MR, Abrahamsen M, Jolles E, Nielson CM, Baggio ML, Silva R, Quiterio M: The human papillomavirus infection in Men (HIM) study: HPV prevalence and type-distribution among men residing in Brazil, Mexico, and the US.
Cancer Epidemiol Biomarkers Prev 2008, 17(8):2036-2043. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED Jr, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, Garner EI, Guris D: External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents.
J Infect Dis 2011, 203:58-65. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A, Phongnarisorn C, Wootipoom V, Yuenyao P, Vipupinyo C, Rugpao S, Sriplienchan S, Celentano DD: The association of hormonal contraceptive use and HPV prevalence.
Int J Cancer 2011, 128(12):2962-2970. PubMed Abstract | Publisher Full Text
Smith E, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP: Tobacco and alcohol use increase the risk of both HPV associated and HPV independent head and neck cancers.
Cancer Causes Control 2010, 21:1369-1378. PubMed Abstract | Publisher Full Text
Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA: Condom use and the risk of genital human papillomavirus infection in young women.
NEJM 2006, 354(25):2645-2654. PubMed Abstract | Publisher Full Text
Wawer MJ, Tobian AA, Kigozi G, Kong X, Gravitt PE, Serwadda D, Nalugoda F, Makumbi F, Ssempiija V, Sewankambo N, Watya S, Eaton KP, Oliver AE, Chen MZ, Reynolds SJ, Quinn TC, Gray RH: Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai.
Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, Charvat B, Ssempijja V, Riedesel M, Oliver AE, Nowak RG, Moulton LH, Chen MZ, Reynolds SJ, Wawer MJ, Gray RH: Male circumcision for the prevention of HSV-2 and HPV infections and syphilis.
NEJM 2009, 360(13):1298-1309. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Smith JS, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females: a global review.
J Adolesc Health 2008, 43:S5-S25. PubMed Abstract | Publisher Full Text
Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D: Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study.
Lancet 2011, 377:932-940. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of human papilloma virus infection in males: a global review.
J Adolesc Health 2011, 48:540-552. PubMed Abstract | Publisher Full Text
Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R: Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.
J Clin Microbiol 1995, 33(8):2058-2063. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK: Genital warts and risk of cancer-a Danish study of nearly 50,000 patients with genital warts.
J Infect Dis 2012, 205(10):1544-1553. PubMed Abstract | Publisher Full Text
Grulich AE, Jin F, Conway EL, Stein AN, Hocking J: Cancers attributable to human papillomavirus infection.
Sex Health 2010, 7:244-252. PubMed Abstract | Publisher Full Text
WHO/ICO Information Centre, Human Papillomavirus and Related Cancers. Summary Report Update. EUROPE; 2010. [Summary Report Update]
http://www.who.int/hpvcentre webcite
Baio GL, Capone A, Marcellusi A, Mennini FS, Favato G: Economic burden of human papillomavirus-related diseases in Italy.
PLoS One 2012, 7(11):e49699. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Vajdic CM, van Leeuwen MT, Jin F, Prestage G, Medley G, Hillman RJ, Stevens MP, Botes LP, Zablotska I, Tabrizi SN, Grulich AE: Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men.
Sex Transm Infect 2009, 85:330-335. PubMed Abstract | Publisher Full Text
Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky JM: Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study.
J Infect Dis 2004, 190:2070-2076. PubMed Abstract | Publisher Full Text
Van der Snoek EM, Niesters HG, Mulder PG, van Doornum GJ, Osterhaus AD, van der Meijden WI: Human papillomavirus infection in men who have sex with men participating in a Dutch gay-cohort study.
Sex Transm Dis 2003, 30:639-644. PubMed Abstract | Publisher Full Text
Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer.
NEJM 1987, 317:973-977. PubMed Abstract | Publisher Full Text
Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R: Correlates of homosexual behavior and the incidence of anal cancer.
JAMA 1982, 247:1988-1990. PubMed Abstract | Publisher Full Text
Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S: Genital warts incidence and healthcare resource utilisation in Australia.
Sex Transm Infect 2010, 86:181-186. PubMed Abstract | Publisher Full Text
Cervarix: Summary of Product Characteristics.
http://www.medicines.org.uk/emc/medicine/20204/SPC/Cervarix webcite
Gardasil: Summary of Product Characteristics.
http://www.medicines.org.uk/emc/medicine/19016/SPC/gardasil/ webcite
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males.
NEJM 2011, 364(5):401-411. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Palefsky J, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
NEJM 2011, 365:1576-1585. PubMed Abstract | Publisher Full Text
Goldstone S: A case assignment methodology for determining quadrivalent HPV vaccine efficacy against AIN in men having sex with men. In 26th International Papillomavirus Conference. Montreal, Canada; 2010.
http://www.eurogin.com/2010/EUROGIN2010_Abstracts.pdf webcite
Lu B, Lu B, Kumar A, Castellsagué X, Giuliano AR: Efficacy and safety of prophylactic vaccines against cervical HPV infection and disease among women: a systematic review & meta-analysis.
BMC Infect Dis 2011, 11:13. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text
Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS, Koutsky LA: Evidence of immune memory 8,5 years following administration of a prophylactic human papillomavirus type 16 vaccine.
J Clin Virol 2012, 53(3):239-243. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Kjaer SK: An evaluation of the Long-term effectiveness, immunogenicity and safety of Gardasil™.
http://www.eurogin.com/2011/Eurogin-2011-Abstracts.pdf webcite
Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A, GlaxoSmithKline Vaccine HPV-007 Study Group: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
Lancet 2009, 374(9706):1975-1985. PubMed Abstract | Publisher Full Text
Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA: Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
Vaccine 2007, 25:4324-4333. PubMed Abstract | Publisher Full Text
Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS, Protocol 016 Study Group: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
Pediatrics 2006, 118(5):2135-2145. PubMed Abstract | Publisher Full Text
Moreira ED Jr, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, Hillman RJ, Ferris D, Coutlee F, Vardas E, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI: Safety and reactogenicity of a quadrivalent human papillomavirus (types 6,11,16,18) L1 viral like particle vaccine in older adolescents and young adults.
Hum Vaccin 2011, 7(7):768-775. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS: Clinical trial and postlicensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine.
Pediatr Infect Dis J 2010, 29:95-101. PubMed Abstract | Publisher Full Text
Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM: A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®.
Vaccine 2010, 28:4719-4730. PubMed Abstract | Publisher Full Text
Oliphant J, Perkins N: Impact of the human papillomavirus vaccine on genital wart diagnoses at Auckland Sexual Health Services.
Bauer HM, Wright G, Chow J: Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010.
Am J Public Health 2012, 102(5):833-835. PubMed Abstract | Publisher Full Text
Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS: Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.
Sex Transm Infect 2009, 85(7):499-502. PubMed Abstract | Publisher Full Text
Fairley CK, Donovan B: What can surveillance of genital warts tell us?
Sex Health 2010, 7(3):325-327. PubMed Abstract | Publisher Full Text
Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, D'Ancona F, Lévy-Bruhl D, on behalf of the VENICE 2 project gatekeepers group: The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
Euro Surveill 2010., 15(47)
Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19730 webcite
Morbidity and mortality weekly report (MMRW) adult vaccination coverage-United states 2010
2012, 61(04):66-72.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a2.htm webcite
Advisory Committee on Immunization Practices (ACIP): Recommendations on the use of quadrivalent human papillomavirus vaccine in males.
Brady MT, Byington CL, Davies HD, Edwards KM, Glode MP, Jackson MA, Keyserling HL, Maldonado YA, Murray DL, Orenstein WA, Schutze GE, Willoughby RE, Zaoutis TE: HPV vaccine recommendations. American academy of paediatrics.
Pediatrics 2012, 129(3):602-605. PubMed Abstract | Publisher Full Text
Australian Government. Department of Health and Ageing. Immunise Australia Program. Human papillomavirus (HPV). Australian Government.
[Accessed 31 July 2011]. [http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv webcite]
Gertig DM, Brotherton JM, Saville M: Measuring human papillomavirus (HPV) vaccination coverage and the role of the national HPV vaccination program register.
Australia. Sex Health 2011, 8(2):171-178. Publisher Full Text
An Advisory Committee Statement (ACS): National Advisory Committee on Immunization (NACI). Update on Human Papillomavirus (HPV) Vaccines.
Jit M, Choi YH, Edmunds WJ: Economic evaluation of human papillomavirus vaccination in the United Kingdom.
BMJ 2008, 337:a769. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Kim JJ, Goldie SJ: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
BMJ 2009, 339:b3884. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Taira AV, Neukermans CP, Sanders GD: Evaluating human papillomavirus vaccination programs.
Emerg Infect Dis 2004, 10:1915-1923. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE: Cost-effectiveness of human papillomavirus vaccination in the United States.
Emerg Infect Dis 2008, 14(2):244-251. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States.
NEJM 2008, 359:821-832. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N: Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Gynecol Oncol 2009, 112:370-376. PubMed Abstract | Publisher Full Text
Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies.
Emerg Infect Dis 2007, 13:28-41. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Cost-effective analysis of anti-HPV vaccination programme in Italy: a multi-cohort Markov model. 2007.
Available at SSRN: http://ssrn.com/abstract=961847 webcite or http://dx.doi.org/10.2139/ssrn.961847 webcite
Favato G, Baio G, Capone A, Marcellusi A, Costa S, Garganese G, Picardo M, Drummond M, Jonsson B, Scambia G, Zweifel P, Mennini FS: Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases.
Med Care 2012, 50(12):1076-1085. PubMed Abstract | Publisher Full Text
Rawlins MD, Culyer AJ: National institute for clinical excellence and its value judgments.
BMJ 2004, 329(7459):224-227. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Mennini FS, Costa S, Favato G, Picardo M: Anti-HPV vaccination: a review of recent economic data for Italy.
Vaccine 2009, 27:A54-A61. PubMed Abstract | Publisher Full Text
Nolan TM: The Australian model of immunization advice and vaccine funding.
Vaccine 2010, 28:A76-A83. PubMed Abstract | Publisher Full Text
Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G: A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical cancer screening program.
Sex Health 2007, 4:165-175. PubMed Abstract | Publisher Full Text
Elbasha EH, Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States.
Vaccine 2010, 28:6858-6867. PubMed Abstract | Publisher Full Text
Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC: Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity.
J Infect Dis 2011, 204(3):372-376. PubMed Abstract | Publisher Full Text
Reece M, Herbenick D, Schick V, Sanders SA, Dodge B, Fortenberry JD: Sexual behaviors, relationships, and perceived health among adult men in the United States: results from a national probability sample.
J Sex Med 2010, 7(Suppl 5):291-304. PubMed Abstract | Publisher Full Text
ECDC guidance. Introduction of HPV vaccines in European Union countries-an update.
http://www.ecdc.europa.eu webcite
Lenzi A, Mirone V, Gentile V, Bartoletti R, Ficarra V, Foresta C, Mariani L, Mazzoli S, Parisi SG, Perino A, Picardo M, Zotti CM: Rome consensus conference - statement; human papilloma virus diseases in males.
BMC Publ Health 2013, 13:117. BioMed Central Full Text
Calore EE, Giaccio CM, Nadal SR: Prevalence of anal cytological abnormalities in women with positive cervical cytology.
Diagn Cytopathol 2011, 39(5):323-327. PubMed Abstract | Publisher Full Text
Weiss TW, Zimet GD, Rosenthal SL, Brenneman SK, Klein JD: Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females.
J Adolesc Health 2010, 47(1):3-11. PubMed Abstract | Publisher Full Text
Palefsky JM: Human papillomavirus-related disease in men: not just a women's issue.
J Adolesc Health 2010, 46(4 Suppl):S12-S19. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Goldstone SE: Some straight talk about anal human papillomavirus infection.
J Infect Dis 2010, 201(10):1450-1452. PubMed Abstract | Publisher Full Text
Oon SF, Winter DC: Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature.
J Med Screen 2010, 17(1):44-49. PubMed Abstract | Publisher Full Text
Brewer NT, Ng TW, McRee AL, Reiter PL: Men's beliefs about HPV-related disease.
J Behav Med 2010, 33:274-281. PubMed Abstract | Publisher Full Text
Hernandez BY, Wilkens LR, Thompson PJ, Shvetsov YB, Goodman MT, Ning L, Kaopua L: Acceptability of prophylactic human papillomavirus vaccination among adult men.
Hum Vaccine 2010, 6:467-475. Publisher Full Text
Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS: Acceptability of HPV vaccine among a national sample of gay and bisexual men.
Sex Transm Dis 2010, 37:197-203. PubMed Abstract | Publisher Full Text
Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE: The cost-effectiveness of male HPV vaccination in the United States.
Vaccine 2011, 29(46):8443-8450. PubMed Abstract | Publisher Full Text
Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J: Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
BMC Cancer 2013, 13(10):1-12. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK: Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.
Sex Transm Dis 2013, 40(2):130-135. PubMed Abstract | Publisher Full Text
Grayson M: From an interview to harald Zur Hausen.
Nature 2012, 488(7413):16. PubMed Abstract | Publisher Full Text
Low MI, Attiga YS, Garg G, Schelgal R, Gllicano GI: Can male vaccination reduce burden of human papillomavirus-related disease in the United States?
Viral Immunol 2012, 25(3):174-183. PubMed Abstract | Publisher Full Text
European Centre for Disease Prevention and Control: Introduction of HPV vaccines in EU countries – an update. Stockholm: ECDC; 2012.
978-92-9193-377–8PubMed Abstract | Publisher Full Text
Michels KB, Zur Hausen H: HPV vaccine for all.
Lancet 2009, 374(9686):268-270. PubMed Abstract | Publisher Full Text
Pre-publication history
The pre-publication history for this paper can be accessed here:


text:
Joanna has a medical condition requiring regular infusions of immune globulin which is derived from plasma donations.Donate Today
Make 3 platelet donations from September 10 - November 30, 2015 and receive your choice of a New York Blood Center microfleece jacket OR 600 BONUS Donor Advantage Points.Schedule Appointment
New York Blood Center (NYBC) is one of the largest independent, community-based, nonprofit blood centers in the United States. Each year, NYBC provides approximately one million blood products to hundreds of hospitals in the Northeast, helping save the lives of cancer and surgery patients, accident and burn victims, AIDS and sickle cell anemia patients, transplant recipients, hemophiliacs, and many others.Learn More
Visit our new Job Search Portal for an intuitive candidate experience with the capability to create and manage your profile, target your job search and apply with ease.Start Job Search
Donor centers in your neighborhood and almost 50 blood drives a day in NY, NJ and beyond. Check the Schedule
Volunteers play a crucial role in helping NYBC save lives each and every day. Learn More
NYBC ended all research on non-human primates more than 10 years ago. Learn More
Science in service of humanity - visit a chronicle of our history and evolution. LEARN MORE
With 17 state-of-the-art laboratories and nearly 100 scientists, we engage in some of the most important health-related research taking place around the world. Find out more
Two thousand volunteer donors a day make miracles happen. My life was saved….
11-year-old Jaralene is hoping for a life-saving bone marrow match. Learn More
Ariel Fishman gives thanks to the 70 blood donors who saved his life.Watch video

subset: commoncrawl


text:
Grace King (GKHS) Class of 1978 Alumni List
Help us Update the Grace King 1978 Class List by adding any names missing from the list below:
Registered Alumni
1978 Class List
- Saundra Bergeron
- Denise Bier
- Celeste Chauvin Boudreaux
- Joan Bryson
- Jeanne Byrd
- Judy Carey
- Jeannette Caronna
- Janet Caston
- Celeste Chauvin
- Paula Phillips Clemons
- Dannielle De Bram
- Belinda Dismuke
- DeGenerese Ellen
- Donna Fontenot
- Janean Frazier
- Kathy Gremillion
- Cheryl Guerra
- Judy Hall
- Nancy Schmitt Hatfield
- Denise Horiast
- Deborah Houston
- Alfreda Jones
- Suzanne Keller
- Diane Yohana Kelly
- Lori Lacoste
- Karen Landers
- Kathleen Wiggins Mapp
- Valerie Marchese
- Sopczak Mary Anne
- Alfreda Jones Miller
- Vickie Misuraca
- Lesley Nichelson
- Alba Olivares
- Lauren Perret
- Janet Piro
- Cheryl Rousselle
- Penny Schexnayder
- Janean Smith
- Barbara Spencer
- Terri Timphony
Know Grace King Class of 1978 graduates that are NOT on this List? Help us Update the 1978 Class List by adding missing names.
Grease was the top movie in theaters in 1978, with a lifetime gross of over $181,813,770. Among TV shows in 1978, Laverne & Shirley was the most popular of the year.
Hit Songs From 1978
Magnet And SteelWalter Egan
(Love Is) Thicker Than WaterAndy Gibb
Dont Let Me Be MisunderstoodSanta Esmeralda
Come Sail AwayStyx
Hot BloodedForeigner
Can't Smile Without YouBarry Manilow
Back In Love AgainL.T.D.
Deacon BluesSteely Dan
Whenever I Call You "Friend"Kenny Loggins
Jack And JillRaydio
Hit Movies From 1978
- Heaven Can Wait
- Every Which Way But Loose
- Jaws 2
Hit TV Shows From 1978
- Vega$ on ABC
- One Day at a Time on CBS
- ABC Sunday Night Movie on ABC
- Happy Days on ABC
- Little House on the Prairie on NBC
Class of 1978 Reunions
Grace King High School News
More 1978 alumni from Grace King HS have posted profiles on Classmates.com®. Click here to register for free at Classmates.com® and view other 1978 alumni.
The Grace King High class of '78 alumni are listed below. These are former students from Grace King High in Metairie, LA who graduated in 1978. Alumni listings below have either been searched for or they registered as members of this directory.
If you are a former student of Grace King High in Metairie, Louisiana, register now to add your name.


text:
New Sportsbook.ag customers: Make your 1st bet, get your 2nd bet free, 100%, winnings paid in cash.Join Now
Already have an account? Click here to view new Exclusive Rewards!
SPOKANE, Wash. (AP) - Siyani Chambers scored 11 points, including five straight in the final two minutes, and 12th-seeded Harvard won its second NCAA tournament game in history, upsetting Cincinnati 61-57 Thursday.
The Crimson became the first Ivy League school with NCAA tournament wins in consecutive years since Princeton in 1983-84.
Harvard never trailed after the opening moments. They played with confidence and scrap against the No. 5 seed Bearcats, who shared the American Athletic Conference regular season title. Sean Kilpatrick led seed Cincinnati (27-7) with 18 points, but the Bearcats failed to win a tournament game for the second straight year.
Copyright 2015The Associated PressAll Rights Reserved


text:
Use our Color Blocks for Melt & Pour to easily tint your soap projects without the worry of specks or having to deal with messy powders. Use these colors in any product that uses M&P soap - like solid sugar scrubs!
To achieve the color concentration in the image above use 4 grams of colorblock in 1 pound of clear M&P soap base.
Ingredients:Botanical Name: Mica, Titanium Dioxide (CI 77891), Cocos Nucifera (Coconut) Oil, Elaeis Guineensis (Palm) Oil, Carthamus Tinctorius (Safflower) Seed Oil, Glycerin, Aqua/Eau/Water, Sodium Hydroxide, Sorbitol, Sorbitan Oleate, Hydrolized Soybean Protein.Common Name: Mica Titanium Dioxide, Coconut Oil, Palm Oil, Safflower Oil, Glycerin, Water, Sodium Hydroxide, Sorbitol, Sorbitan Oleate, Soybean Protein
Watch a quick video on how easy it is to use Color Blocks on the Soap Queen Blog
Terah from Bramble Berry replies...Hi Andrea! I'm so glad you're in love with our color blocks! We love them too! We haven't tested this, but I don't see why you wouldn't be able to use these color blocks with other bases. Though, please keep in mind our color blocks work best in a clear base versus a white one. I will email you personally to get the specifics!
Terah from Bramble Berry replies...Hi Meghan Kelsey! You're right! In an opaque base like our Goat Milk Melt And Pour this color block would not really show up. This colorant needs the light to shine through to be able to catch its wonderful shimmer. I suggest using our Clear Melt and Pour Soap Base to really showcase our Shimmer Super Pearly White Color Block. I will email you personally to discuss this further.
"Thank you for your prompt response. Bramble Berry has the best customer service of any company I know of. Pass the word!" -Rene
Linda O'Sullivan (also known as Mimi and Boo) creates stunning cold process soap and bath fizzies in the UK. I first came across her soaps on Instagram, via the hashtag #SoapShare. I quickly found myself scrolling through her dreamy Instagram feed, feeling incredibly inspired. All of Linda's creations are elegant and sophisticated. I love how […]
The post How Leaning on Books Improves Product Photography appeared first on Soap Queen.


text:
More Junior High and Middle School Talksheets-Updated!: 50 More Creative Discussions for Junior High Youth Groups - eBook
- All Products
- Academic
- Accompaniment Tracks
- Audiobooks
- Bible Accessories
- Bible Covers
- Bible Studies & Curriculum
- Bibles
- Books
- Buy in Bulk
- Catholic
- Children
- Christian Living
- Christmas
- Church & Pastoral
- Church Supplies
- Closeouts
- Clothing & Accessories
- Crafts & Recreation
- Download
- DVDs
- eBooks
- eBooks On Sale
- Family
- Fiction
- Gift & Home
- Homeschool
- Last Chance Bargains
- MP3 Music Downloads
- Music
- New Release
- Non-Fiction
- Pre-Order
- Slightly Imperfect
- Software
- Spanish
- Subscriptions
- Sunday School
- Teens
- Videos
ChristianBook eBooks on nook
To read a Christianbook.com licensed eBook on your nook device, you will need to use Adobe Digital Editions.
Plug your nook into the computer and open Adobe Digital Editions.
If this is your first time plugging your nook into ADE, you will need to authorize your nook in order add eBooks.
Once plugged in, your nook will be displayed in the left column of Adobe Digital Editions under the Bookshelves.
When you've chose an eBook that you wish to add to your nook, click and drag the eBook over the nook icon and let go when you see the green plus symbol.
After you've added your eBooks to your nook, you can unplug the device from your computer and access your Library.
To access your Christianbook.com licensed eBooks, first click the orange "My Library" button on the nook home screen to access your eBooks.
Next, click on "View My Documents" at the bottom of your nook's navigation screen.
Use the arrows to browse and then click the circle on the right side to select your eBook.
You are now ready to enjoy your eBook!
Have questions about eBooks? Check out our eBook FAQs.
Product Information
|Format: DRM Protected ePub
Vendor: Zondervan/Youth Specialties
Publication Date: 2010
Availability: In Stock
Series: TalkSheets
Publisher's Description
Start Discussions That Matter to Your Junior Highers & Middle Schoolers About God. About themselves, their, beliefs, their questions, their lives. More Junior High-Middle School TalkSheets--Updated! contains the same kind of provocative, compelling, discussion-starting questions that are hallmarks of the best-selling TalkSheets series--now updated for new-millennium students. Here are 50 more creative discussions that focus on relevant, real-life topics: The Future Death Priorities AIDS Heaven & Hell Premarital Sex Prayer Knowing God Homosexuality Materialism & Consumerism . . . and 40 more subjects of perennial interest to teenagers. TalkSheets are convenient, effective one-page reproducible handouts with intriguing questions that will get churched kids and unchurched kids alike talking and thinking about the Bible--and how its principles affect their daily lives. Use TalkSheets to launch your own lesson--or use them as stand-alone Bible studies. Each TalkSheet comes with detailed information and suggestions for discussion leaders: Bible references galore, Internet resources, further group exploration, and activities to pursue during and after the meeting. More Junior High-Middle School TalkSheets--Updated! is the perfect discussion-starting resource for youth meetings, small groups and cell groups, Sunday school, and camps and retreats.
Author Bio
Product Reviews
Ask Christianbook
Ask Christianbook
Find Related Products
- Church & Pastoral >> Youth Ministry >> Activities
- Church & Pastoral >> Youth Ministry >> Series
- Church & Pastoral >> Youth Ministry >> Youth Leader Resources >> Youth Meetings
- Download >> eBooks >> Church & Pastoral >> Youth Ministry
- eBooks >> Church & Pastoral >> Youth Ministry >> Activities
- eBooks >> Church & Pastoral >> Youth Ministry >> Series
- eBooks >> Church & Pastoral >> Youth Ministry >> Youth Leader Resources >> Youth Meetings
- Start A New Search


text:
On November 5, 2011, a 23-page Grand Jury report rocked Penn State to its foundation. As a result of Jerry Sandusky being convicted on 45 of 48 counts sexual abuse against 10 minors and subsequent fallout and alleged coverup by several key school administrators and legendary coach Joe Paterno, these events will forever be a dark stain in the history of our University.
On July 23, 2012, the NCAA imposed unprecedented sanctions on Penn State's football program following investigations into the Sandusky Scandal. Three years later, Penn State football isn't just still here — it's alive and thriving.


text:
- Cavalcade of Bands set for Halloween
- The Rooster Crows in Lititz
- Art about town
- More Chocolate Walk stops revealed
- Lowe's, Aaron's Acres team to upgrade Manheim park
- Flying high for fun — for now
- Countdown to Chocolate Walk
- Fisher is new borough manager
- The Manheim Project gives back to the community
- Teens put on the BRAKES for safe driving course
Fresh Air kids enjoy local hospitality
By: JACQUELINE WATSON Record Express Correspondent, Staff Writer
Surveying the rows of corn and freshly-mowed fields that almost reach Mark and Rosalee Massie's doorstep in Lititz, it is easy to see how this place could be a refreshing experience for children from New York City.
Rev. Willard Parsons of Pennsylvania implemented his plan for the Fresh Air Fund in 1877. Over the years, it has grown into the organization it is today with over 9,000 students annually participating in their numerous programs throughout 13 states and two countries. These programs include Fresh Air Fund camps, educational programs, and visits to volunteer families who open their homes to the children.
Depending on the prior agreement of the children and the host family with the Fresh Air Fund, these visits can last anywhere from a week to all summer. The host families are screened for safety purposes, but are not required to have fancy cars or expensive hobbies to give children a fun vacation away from the big city. Through volunteers and donations, the Fresh Air Fund is able to offer these opportunities free of charge to children of New York City. One of the many local host families is the Massie family.
The Massie family may not be able to claim the Beverly Hills Walk of Fame, but in their Lancaster County rural locale, they have the "Walk of Massie" to be proud of. At least that is what 9 year old FAF visitor Marialicia Franqui calls the driveway leading to the Massie house, which has been covered with sidewalk chalk art by the children. Some of the phrases 10 year old FAF visitor Noveli Carlo wrote with the chalk included things such as "Ms. Rosalee and Mr. Mark are the nicest host family ever."
In addition to Noveli and Marialicia, the Massies have three daughters — Katelyn, Brianna and Melody. The playmate closest to the visitors' ages is Katelyn. Marialicia notes, with admiration, how tough Brianna is. The youngest, Melody, shares her sweet smile. Energy seems to fill the girls and spill out into their chatter and actions. Some might find the surrounding vitality daunting, but it is clear that host parents Mark and Rosalee Massie enjoy it and the kids do not seem to use the energy to misbehave.
"They always bring a lot of life into the house," commented Rosalee.
Marialicia, of the Bronx, New York is not shy of strangers, cameras, or attention. She is very expressive as she eagerly participates in any topic discussed. She even demonstrates what they refer to as a Jamaican dance that she has tried to teach to the Massie family and Noveli.
Noveli is from Brooklyn and had already made friends with Marialicia on the bus to Lancaster before realizing that they would be staying at the same house. Noveli is quiet at first, but quickly warms up and shows her friendliness.
"They make me feel like this is my family," said Noveli of the Massie family.
According to Noveli and Marialicia, both their moms signed them up because they felt it would be a good experience for them. It is not just a chance for literal fresh country air, but also fresh experiences and new learning. One of the first things Marialicia commented on was having her own room to share with Noveli and pointed out that it was the first house she has stayed in. They also visited local attractions such as Hershey Chocolate World and the Lititz Fourth of July Parade. They, of course, have had their moments of homesickness, but they already asked if they could come back again next year.
"They asked me if I'd consider having them back. I said 'of course,' I don't even have to think about it," noted Rosalee Massie.
Rosalee Massie spent her childhood growing up in different cities and now that she lives in the country she does not desire to return. The Fresh Air program gives her the chance to share the treasures she has found in the country with those who might otherwise never get to experience them.
"We wanted to kind of help out and make a difference in kid's lives," said Mark.
Mark and Rosalee Massie enjoy meeting new people and appreciate the opportunity to interact with Noveli and Marialicia's moms on the phone. They also note that they love having company and the five girls are good playmates for each other.
It is a cultural learning experience for both the visiting and the host family. This facet comes into the conversation as Marialicia wheedles the reserved Mark Massie into saying "ya mon," one of the Jamaican phrases she claims credit for teaching him.
"Just worth it to have these kids in our home and it's a lot of fun and just to see the joy…it's not perfect, but it's all worth it…to have them experience something new, and I think it's good for the family too to have different cultures in your home," Rosalee commented.
According to Rosalee, the children delight in spending most of their days outside. Between meals, they barely take the time to brush their teeth and clear their plate before running outside. Both Noveli and Marialicia marvel at the large yard and all the wonders associated with it. All five of the children animatedly describe the birds whose nest was knocked from a tree in the yard during a storm. They interject details as Rosalee relates the story of how they helped rescue the nest and the baby birds, from the day they were found scattered on the ground to the day they all took flight. Few kids from the city can claim having helped rescue a whole nest full of baby birds this summer.
Thanks to the Fresh Air Fund and host families like the Massies, these kids can go home with their hearts full of these precious rural and Central Pennsylvania memories. More FRESH AIR, page A14
About Lititz Record
Latest News
Hops'pitality at the Lititz Craft Beer Fest
An Ohio brewer provided an early buzz at the Lititz...
- Posted October 1, 2015
- 0
The Benefits of Beer: Ambucs lead the way in a changing Lititz
In two short years, the Lititz Craft Beer Fest has...
Who Cares? Lititz Cares
UPDATE: This event has been canceled due to inclement weather...
Pope Pilgrimage: Locals Recount Unforgettable Sunday in Philadelphia
Dara Burkholder Morales told her mother she was having "another...
Ronald Lee Getz, 70, worked at Case New Holland, Penryn Fire Company volunteer
Ronald Lee Getz, 70, formerly of Penryn, passed away Friday,...
Matthew C. Hines, 30, WHS grad, Eagle Scout, worked for Liberty Therapy Solutions, sports fan
Matthew C. Hines, 30 of Norristown, passed into eternal rest...
Doris M. Johnson, 93, mother of three, needlework instructor, designer, enjoyed gardening
Doris M. Johnson, 93, of Lititz, passed away peacefully Sept....
Hops'pitality at the Lititz Craft Beer Fest
An Ohio brewer provided an early buzz at the...
- October 1, 2015
- 0
The Benefits of Beer: Ambucs lead the way in a changing Lititz
In two short years, the Lititz Craft Beer Fest...
- September 30, 2015
- 0
Who Cares? Lititz Cares
UPDATE: This event has been canceled due to inclement...
- September 30, 2015
- 0
Ronald Lee Sandhaus, 69, popular Lititz police officer, HAM radio enthusiast
Ronald Lee Sandhaus, 69, 533 Spring Avenue, Lititz, passed...
- July 23, 2014
- 3
Lititz Woman's Club is off to the races
The Lititz Woman's Club is holding its second annual...
- April 7, 2015
- 2
Reel Reviews
'Dolphin Tale 2' Flipper is back! Well, not really....
- September 17, 2014
- 2
Michael C. Upton says:
Barbara Dayan says:


text:
Submissions from 2014
Private Lives and Interior Spaces: Raja Ravi Varma's Scholar Paintings, Niharika Dinkar
Radical Theatrics: Put-ons, Politics, and the Sixties, Craig J. Peariso
Representing Black Power: Handling a "Revolution" in the Age of Mass Media, Craig J. Peariso
Submissions from 2013
Styleless Style? What Photorealism Can Tell Us About "The Sixties", Craig J. Peariso
Bitter Milking Art Education? (Re)orienting, (Re)deeming, (Re)claiming, (Re)presenting M(other)work in Art Education, Anniina Suominen Guyas, Linda Hoeptner Poling, and Kathleen Keys
Submissions from 2012
Traditional and Contemporary Bhutanese Thanka Paintings by Phurba Namgay, Kathleen Keys
The Mystery of the Silkworm: Conversations in the Reading Room and Beyond, Janice Neri and Danielle Skeehan
Mothering Curricula, Linda Hoeptner Poling, Anniina Suominen Guyas, and Kathleen Keys
From Caves to Cathedrals: Visual Arts in Ancient and Medieval Texts, Lee Ann Turner
Submissions from 2011
Cultivating Interiors: Philadelphia, China, and the Natural World, Janice Neri
The Insect and the Image: Visualizing Nature in Early Modern Europe, 1500-1700, Janice Neri
Submissions from 2010
Masculine Regeneration and the Attenuated Body in the Early Works of Nandalal Bose, Niharika Dinkar
Books from 2009
Kavousi IIA, the Late Minoan IIIC Settlement at Vronda: The Buildings on the Summit, Leslie Preston Day, Nancy L. Klein, and Lee Ann Turner
Mrs. Delany's Natural History and Zoological Activities: "A Beautiful Mixture of Pretty Objects", Janice Neri
Jelly Fish Pendant Project, Anika Smulovitz
Books from 2008
John Taye: The Quiet Art of Drawing, John Taye, Kirsten Furlong, and Richard Young
Submissions from 1997
Ageing in American Comic Strips: 1972-1992, Heather Hanlon, Judy Farnsworth, and Judy Murray


text:
30 results was found matching keyword
0 vote(s)Comment
Báo Thanh Niên English 1 month(s) ago
Syrian government forces recaptured four northwestern villages on Tuesday in a counter-attack on insurgents threatening strongholds of President Bashar al-Assad, a monitor said.
Keywords: InsurgentstankThe ArmyVillagesstand guard
VietnamNet English 2 month(s) ago
VietNamNet Bridge – Viet Nam plans to start a new scheme to monitor environmental resources to prevent natural disasters, the Ministry of Natural Resources and Environment (MONRE) has said.
Keywords: ResourcesWater ResourcesHydrocraftDisastersMonreVillages
Báo Dân Trí English 2 month(s) ago
1 related news
Vietnam plans to start a new scheme to monitor environmental resources to prevent natural disasters, the Ministry of Natural Resources and Environment (MONRE) has said.
Keywords: ResourcesWater ResourcesHydroDisastersImagesplanSouth East Asian
VOV News English 2 month(s) ago
1 related news
Keywords: ResourcesWater ResourcesHydroplanSouth East AsianNational Action Plan
Báo Thanh Niên English 2 month(s) ago
Syrian rebels, including Al-Qaeda-affiliated fighters, have fired hundreds of rockets and mortar shells on two besieged Shiite-majority villages in the northwestern province of Idlib, a monitor said Tuesday.
Keywords: mortarVillagesRocketsAl QaedaThe Army
Báo Thanh Niên English 3 month(s) ago
1 related news
The Islamic State group has beheaded two women in Syria on accusations of "sorcery," the first such execution of women in Syria, the Syrian Observatory for Human Rights monitor said Tuesday.
Keywords: stateHuman RightsturnbackBelievedBritain
Báo Thanh Niên English 5 month(s) ago
US-led strikes targeting the Islamic State group killed at least 52 civilians in northern Syria, a monitor said Saturday, but the Pentagon said it could not confirm the report.
Keywords: The RebelattackAttacksThe PentagonconfirmHuman Rights
VietnamNet English 7 month(s) ago
1 related news
The Ministry of National Defence told eight provinces and relevant ministries to closely monitor forestry projects implemented by foreign companies in Viet Nam, Tuoi tre (Youth) newspaper reported.
Keywords: Nghe An ProvincedocumentprojectQuang NinhHa Cong TuanTreesNational Defence
VietNam News English 7 month(s) ago
1 related news
Báo Dân Trí English 8 month(s) ago
At least 35 Islamic State jihadists were killed on Sunday in clashes with Syrian Kurdish fighters around the flashpoint town of Kobane, a monitor said.
Keywords: ClashesImagesFightingGamesHuman Rights
Báo Thanh Niên English 8 month(s) ago
A Syrian woman stoned by the jihadist Islamic State group for alledged adultery and left for dead has miraculously walked away from the brutal punishment, a monitor said Friday.
Keywords: Al QaedamiraculouslyIn JuneHuman RightsBritainfleeopen fire
VietNam News English 9 month(s) ago
1 related news
The National Remote Sensing Department under the Ministry of Natural Resources and Environment is working with the Viet Nam Administration of Seas and Islands on a project monitor sea and island resources using remote sensing technology.
Keywords: ResourcesscalecenterprojecthelpIslands
Báo Thanh Niên English 11 month(s) ago
Brazil builds an observation tower in the middle of the Amazon, set to be the tallest of its kind in the world, to monitor climate change.
Keywords: Observation Towerset
Báo Thanh Niên English 12 month(s) ago
Engineers in Mexico have developed a jacket designed to monitor a users vital signs and fitness level while running. The wearable technology is made of breathable fabric to keep a jogger cool while feeding performance information via bluetooth to a smartphone in real time.
Keywords: BluetoothEngineerscoolUsersSignshave
VietnamNet English 15 month(s) ago
VietNamNet Bridge - The Vietnam Civil Aviation Administration (CAAV) has decided to establish a special team to monitor flights of domestic air carriers to deal with the delays and cancellations of flights.
Keywords: FlightsPassengersAirlinesLai Xuan ThanhestablishImages
Top page
| Sign up |
Forgot password
News collection and classification on Baomoi were automatically processed by a computer program.
Publication permit No. 46/GP-TTĐT, Ministry of Information and Communications.
Copyright © by EPI Join Stock Company. All rights reserved.


text:
In the News captures articles, publications, and blog posts by sources outside of Internews.
(This article from DW Akademie discusses including freedom of expression in the UN's Post 2015 Development Framework, an issue that Internews and other NGOs supported in a declaration.)
(Internews' Listening Post project in New Orleans is covered in this article from the Chronicle of Philanthropy - subscription required.)
Two residents offer their thoughts on violence in New Orleans at City Park. (Photograph by Bryan Tarnowski)
(Following is a chapter contributed by Internews Journalism Advisor Eva Constantaras to the new Ibero-American data journalism manual.)
(Internews Data Journalism Advisor Eva Constantaras was interviewed by Visual Loop.)
(Internews' data journalism work in Kenya is discussed in this article from Open Development Toolkit.)
The journalists had questions:
(Internews' unique humanitarian information project in South Sudan is described in this article from enough.)
(John Gatluak, Managing Editor of the Internews Community Radio Network in South Sudan, is profiled in this article from CCTV America.)
(Internews' data journalism work in Kenya is covered in this post from The Infogram Blog.)
(Internews is participating in the summit mentioned in this article from AIDF.)
Update - January 26, 2015: This article made Visual Loop's 50 great data viz articles of 2014.
(Eva Constantaras, Internews Data Journalism Advisor in Kenya, wrote this blog post for School of Data about her experience training journalists in data journalism.)


text:
BPL Community Profile
Clayton Mauritzen (GlacierRambler) - BPL Forum Member
You cannot send this user a personal message (PM) because they have not specified a PM email address yet.
All Forum Posts by Clayton Mauritzen
Re: Yellowstone Flies
Richard nailed it. Both of those shops have a golden reputation in the fly fishing world--second to none. Also consider Yellowstone Anglers (in Livingston, I believe) if you're looking for ...
Re: Entry level backpacking fly rod
For entry level, consider tenkara or a lighter Western rod. Tenkara simplifies things a lot, so it's easier to pick up and do better. Western rods (with reels) are a little more challenging t...
No Penalty
I'll just quote what I've said before on the subject: No pad is "too hot"--they're only more efficient. Basically, both a three-season and winter pad have the insulation to...
Re: Sold
***SOLD***: Complete Tenkara Set-Up
***SOLD*** I'm selling a Daiwa Kiyose 43MF with everything you need to get out on the water and fish for ***SOLD***, including CONUS shipping (I will gladly ship elsewhere for the difference...
Re: Updates
The Going-to-the-Sun Road opened up to Logan Pass recently, as firefighting efforts continue to work reasonably well so far. I'll reiterate what the park has been at pains to say (especially s...
Re: Frontcountry & Backcountry Closures
I should mention that Glacier has gone out of its way in press releases, etc. to point out that the majority of the park is open and unaffected by the fire--only the vicinity of Logan Pass and St. ...
Re: Reynolds Creek Campground
Based on what I can ascertain--NPS descriptions & press releases, social media accounts, and a very helpful picture a pilot posted on Facebook as he flew over the early stages of the fire--the ...
Re: Reynolds fire online map with GIS layers
This is really nice Joseph. Thanks.
Visual Estimates
I did a visual estimate of the affected area and general location using the Google Maps Area Calculator to put this in perspective. Obviously this is not the actual area burning--it would be much ...
All Reader Reviews by Clayton Mauritzen
Clayton Mauritzen has posted no reviews.


text:
Comedian David Letterman (L) and actor Dustin Hoffman attend the Kennedy Center Honors reception at the White House on Dec. 2, 2012 in Washington. The Kennedy Center Honors recognized seven individuals - Buddy Guy, Dustin Hoffman, David Letterman, Natalia Makarova, John Paul Jones, Jimmy Page, and Robert Plant - for their lifetime contributions to American culture through the performing arts. / Brendan Hoffman Getty Images
WASHINGTON (AP) - The Kennedy Center for the Performing Arts has a new process to select artists who receive one of America's top arts prizes, the Kennedy Center Honors, after an outside group last year said Latinos have been largely excluded.
Under the revised process, the Kennedy Center will begin seeking recommendations from the public for the first time in the award's 35-year history. Recommendations can be submitted online beginning Thursday. The center will also seek more recommendations from a committee of artists.
To narrow the roster of potential honorees, the center is forming a new Special Honors Committee. Former honorees Chita Rivera and Yo-Yo Ma will serve on the panel, along with opera singer Harolyn Blackwell, dancer Damian Woetzel and two center board members, Elaine Wynn and Cappy McGarr. From there, the Kennedy Center chairman, president and award producers will create slates of potential honorees to balance the selections across artistic disciplines, and the executive committee of the center's board of trustees will make the final decision.
The Kennedy Center Honors have become a major cultural prize for excellence in dance, music, theater, movies or television. The honor includes a salute from the president and secretary of state each year, along with performances by top entertainers. The show is broadcast each December on CBS.
Last year, the National Hispanic Foundation for the Arts criticized the center, saying it has long excluded Latinos from the prize. Two of the more than 180 past honorees were Hispanics - Placido Domingo, the acclaimed Spanish tenor, and Rivera, the actress and singer of Puerto Rican descent. The group suggested potential Latino honorees could include Carlos Santana, Rita Moreno, Joan Baez, Gloria Estefan and others.
Giselle Fernandez, a former journalist who was born in Mexico and appointed by President Barack Obama to the Kennedy Center's board, said the revised process opens up a bigger universe of candidates for consideration.
"You're going to see much more diverse and expansive access to excellence in all disciplines, all realms and all communities," Fernandez said. She added that the Kennedy Center could provide a model for other organizations seeking to reflect America's diversity.
Beyond considering more Latinos, she said a broader selection process will be open "to all communities that perhaps didn't have access before because the process was too closed over the years." Facing criticism was uncomfortable but resulted in a better process, she said.
In January, the center announced a formal review of the Honors with an advisory panel that included Latino arts groups, such as the Latin Academy of Recording Arts and Sciences and the National Association of Latino Arts and Culture.
Kennedy Center Chairman David Rubenstein also met with Felix Sanchez of the National Hispanic Foundation for the Arts, who publicly criticized the center last year for excluding Latinos for years.
In addition to the revised selection process, the Kennedy Center said Thursday that it is committed to bolstering its track record on diversity and its relationship with the Hispanic community. The center is working to form a Latino Advisory Committee to meet quarterly, said spokesman John Dow.
Copyright 2015 USATODAY.com
Read the original story: Kennedy Center announces new Honors selection process


text:
View Singles in Morton
By clicking continue, I agree to receive transactional and promotional emails from Match.com. I understand that I am free to withdraw consent at any time.
By using our site, you agree to the Match.com Terms of Use.
Search for your match in the Hoosier State and find online personals in Indiana. Relationships are a two-way street, start searching for your match today! Subscribe now and start emailing singles in Morton, Indiana today! Addicted to love? Get your fix through thousands of Morton profiles all looking for love.
Alamo, Amo, Annapolis, Bainbridge, Belle Union, Bellmore, Bloomingdale, Brazil, Bridgeton, Carbon, Catlin, Cloverdale, Coatesville, Coloma, Coxville, Crawfordsville, Diamond, Fillmore, Greencastle, Harmony, Hollandsburg, Jamestown, Judson, Knightsville, Ladoga, Limedale, Mansfield, Marshall, Mount Meridian, New Market, New Ross, North Salem, Putnamville, Reelsville, Roachdale, Rockville, Russellville, Stilesville, Wallace, Waveland view all states »